about
Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10Post-exposure passive immunisation for preventing rubella and congenital rubella syndromePost-exposure passive immunisation for preventing rubella and congenital rubella syndromeComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesTherapeutic antibodies, vaccines and antibodyomesStructural definition of a conserved neutralization epitope on HIV-1 gp120Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designNew approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccinationBroadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral SerotypeTRIM21: a cytosolic Fc receptor with broad antibody isotype specificityAdvances in structure-based vaccine designA Blueprint for HIV Vaccine DiscoveryAntibody responses to envelope glycoproteins in HIV-1 infectionCD4 T-cell immunotherapy for chronic viral infections and cancerEarly IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responsesMechanisms of hemagglutinin targeted influenza virus neutralizationCharacterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus MacaquesHuman combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virusSang Froid in a time of trouble: is a vaccine against HIV possible?Antibodies against viruses: passive and active immunizationComplement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile VirusVaccines: the Fourth CenturyEnhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue DiseaseIn vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopesCrystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33Rational HIV Immunogen Design to Target Specific Germline B Cell ReceptorsAutoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusA common solution to group 2 influenza virus neutralizationProof of principle for epitope-focused vaccine designStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryReverse vaccinology 2.0: Human immunology instructs vaccine antigen designA hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humansWhat Are the Most Powerful Immunogen Design Vaccine Strategies?Potential of zoonotic transmission of non-primate foamy viruses to humans.Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-NPassive immunization against HIV/AIDS by antibody gene transfer.Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease.
P2860
Q21089590-425FFE95-D965-4883-94AE-3982C33DEB1FQ24187272-C0431693-FABC-463D-ACC6-12606D3C851AQ24202473-8A913C3E-B734-4092-902E-B065E10C380EQ24561905-E3C83B4A-7D52-4898-9C7A-1103B5E3CE40Q24599662-D5C1E3B0-2EAA-42BB-BBDF-DE9BA4A2B0D7Q24655948-208CE3B1-2C86-4FDB-9F8D-E5948FF15E4EQ24679395-233A9CA0-D45C-4221-BBC2-B92D6DC72E5BQ24800305-56FBF510-2388-4040-A9EE-E1F5FC9B4A25Q26252060-C8431F7A-94B2-412E-BAF9-A1B545D48C4EQ26779753-8175F14E-AD85-4E2D-8F1A-A11C6FBA5787Q26824545-7C4A27AE-15D0-4BFD-9E28-2761550DA406Q26829865-1B7B5556-BA27-421D-AE6C-6E464B14C107Q26991572-587931CF-2A45-4240-AAE1-63AA978CF6DBQ27022957-EC944E10-87B6-4FD8-AAC2-147EF6D5BC19Q27300788-07C24D3C-0A45-414D-8E5E-15ED4530CCCAQ27302234-9A3C5F2B-0334-4152-AF5B-F62BE2A55EFAQ27477541-88ECBB19-518F-4762-B4D2-34DB04B4EEC2Q27481388-5E4A7404-EC5E-42D3-B136-58726E4027FCQ27487961-D98B819A-8656-41D9-A916-CA8264C76D48Q27489392-7FBFEDAF-7234-4C14-8B29-E8A7895FEB44Q27490423-DB275E82-4E61-481A-9016-C81FDC769459Q27490454-F546E16B-67C3-43A4-AC6F-F8EDBE8133F4Q27490947-FCC04ED9-78CB-4E4F-B27D-191111D79C7FQ27491029-08A6E219-E8FF-4C90-BBF1-9EECD67A7A25Q27662167-34B19B74-D205-4DBF-AB3C-810322DB4EA9Q27663293-6167C9C9-3746-4C2B-AB51-4F180A2058E2Q27673031-E943B83A-DD1B-4EDF-A810-CB468E649AADQ27677104-5881B2CA-F90D-4BE6-8539-EAADC1C48D06Q27680125-4E139D07-4CF5-473A-A1E3-84F4DD962508Q27680499-39643C98-99B2-40A5-9F04-29FA90697214Q27680873-42627F86-7F88-4FE2-902C-E5D65B1295D3Q27681593-CC502364-3ABB-4553-BD33-751488E5F147Q28071559-F494B1FA-3501-443F-B3FB-7A7EBB1BAA3BQ28075274-866E079D-D591-4134-8EE7-0AF52286AE42Q28488268-FD0277D5-4271-4CC6-859A-F9CA73441E69Q28729792-DEE4D670-F344-4070-BFCA-0A208FBCB8E1Q30336260-9EBCE627-2F01-4777-AB44-D098EF3555FDQ30357096-37604648-8BCE-4DB1-8BF0-996049393559Q30358434-5A2719E7-92D7-4DAE-B984-553BE3940159Q30395259-640FEF1C-E280-4DFB-AE61-EF12CE8FC7E2
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antibodies, viruses and vaccines.
@ast
Antibodies, viruses and vaccines.
@en
Antibodies, viruses and vaccines.
@nl
type
label
Antibodies, viruses and vaccines.
@ast
Antibodies, viruses and vaccines.
@en
Antibodies, viruses and vaccines.
@nl
prefLabel
Antibodies, viruses and vaccines.
@ast
Antibodies, viruses and vaccines.
@en
Antibodies, viruses and vaccines.
@nl
P356
P1476
Antibodies, viruses and vaccines.
@en
P2093
Dennis R Burton
P2888
P304
P356
10.1038/NRI891
P577
2002-09-01T00:00:00Z
P5875
P6179
1018512919